Complement and cellular cytotoxicity in antibody therapy of cancer (Q56656130)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18476787%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

review article

1 reference

title

Complement and cellular cytotoxicity in antibody therapy of cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18476787%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18476787%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

author name string

Siao-Yi Wang

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18476787%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

language of work or name

English

0 references

publication date

1 June 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18476787%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Biological Therapy

7 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18476787%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

volume

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18476787%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18476787%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

page(s)

759-768

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18476787%20AND%20SRC:MED&resulttype=core&format=json

High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice

7 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Development trends for monoclonal antibody cancer therapeutics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Complement before molecular biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Rituximab (anti-CD20) therapy of B-cell lymphomas: direct complement killing is superior to cellular effector mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Complement activation determines the therapeutic activity of rituximab in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Complement-mediated mechanisms in anti-GD2 monoclonal antibody therapy of murine metastatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: relationship to in vivo rituximab resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Controlling complement resistance in cancer by using human monoclonal antibodies that neutralize complement-regulatory proteins CD55 and CD59.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Mapping of the C1q binding site on rituxan, a chimeric antibody with a human IgG1 Fc

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Engineered antibodies with increased activity to recruit complement

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Therapeutic approaches for transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Pharmacokinetics of CAMPATH-1H: assay development and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Fc receptors are required in passive and active immunity to melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Reshaping human antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Engineered antibody Fc variants with enhanced effector function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Effect of glycosylation on antibody function: implications for genetic engineering

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Glycosylation and biological activity of CAMPATH-1H expressed in different cell lines and grown under different culture conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Interleukin-12 and the regulation of innate resistance and adaptive immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Ex vivo-activated human macrophages kill chronic lymphocytic leukemia cells in the presence of rituximab: mechanism of antibody-dependent cellular cytotoxicity and impact of human serum.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

The neu oncogene encodes an epidermal growth factor receptor-related protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Amplification of a novel v-erbB-related gene in a human mammary carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Expression of calcium-permeable cation channel CD20 accelerates progression through the G1 phase in Balb/c 3T3 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

CD20: a regulator of cell-cycle progression of B lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Suppression and promotion of tumor growth by monoclonal antibodies to ErbB-2 differentially correlate with cellular uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

CD20-mediated apoptosis: signalling through lipid rafts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Novel immune-based treatment strategies for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.8.6.759

21 January 2018

Identifiers

DOI

10.1517/14712598.8.6.759

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18476787%20AND%20SRC:MED&resulttype=core&format=json

7 January 2020

1 reference